🇺🇸 D-0502 in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 23 April 2025 – 23 April 2026
Total reports: 4

Most-reported reactions

Acute Kidney Injury — 1 report (25%)
Dizziness — 1 report (25%)
Obstructive Pancreatitis — 1 report (25%)
Pneumonia — 1 report (25%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is D-0502 approved in United States?

D-0502 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for D-0502 in United States?

InventisBio Co., Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.